ShangBay Capital’s William Dai Recognized Among GrowthCap’s Top 25 Healthcare Investors for 2024
May 03 2024 - 12:00PM
Business Wire
ShangBay Capital, a prominent venture capital firm specializing
in healthcare investments, proudly announces the inclusion of
William Dai in GrowthCap's esteemed list of top healthcare
investors for 2024.
This prestigious accolade celebrates William Dai's exceptional
contributions as one of the foremost investors in the healthcare
sector, alongside a distinguished cohort of industry leaders. The
selection criteria focused on investment expertise, track record,
impact on the healthcare landscape, and support for portfolio
company growth.
William Dai, Founding Managing Partner at ShangBay Capital,
spearheads the firm's healthcare investment initiatives, with a
particular emphasis on medtech ventures. Since its inception in
2015, ShangBay Capital, under William's leadership, has emerged as
a successful venture capital entity, nurturing 67 portfolio
companies and achieving multiple successful exits. William
currently holds board positions in esteemed companies such as
Luminopia, Aqua Medical, Meditrina, FemDx, Laplace Interventional,
and YorLabs. He has previously served on the boards of NeuroVasc
(acquired in 2019) and Arrinex (acquired by Stryker in 2019).
With over two decades of experience in corporate finance,
mergers and acquisitions, and capital markets across Asia and the
U.S., William Dai brings a wealth of expertise to the healthcare
investment realm. Prior to founding ShangBay Capital, he held CFO
positions at ShangPharma (NYSE: SHP), Nepstar Corporation (NYSE:
NPD), Microport Scientific Corporation (HK: 00853), and Boston
Scientific China, where he played pivotal roles in driving business
transactions and fostering organizational success.
"ShangBay Capital is deeply committed to supporting visionary
entrepreneurs who are addressing today's unmet clinical needs. The
global healthcare landscape has witnessed unprecedented challenges
during the recent pandemic, underscoring the critical importance of
disruptive healthcare solutions. It is immensely gratifying to
collaborate with exceptional founders and contribute to the
advancement of medical technologies that enhance patient outcomes
and save lives," remarked William Dai.
To learn more about the ranking, visit:
https://growthcapadvisory.com/the-top-25-healthcare-investors-of-2024/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240503579273/en/
For media inquiries, please contact: ShangBay Investor Relations
investorrelations@shangbaycapital.com